Thiogenesis Therapeutics, Corp. (TTI.V)

0.7400 -0.0300 (-3.90%) At close: 03:38PM EDT

Thiogenesis Therapeutics, Corp.

4 King Street West
Suite 401
Toronto, ON M5H 1B6
Canada
888-223-9165
https://www.thiogenesis.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Patrice P. Rioux M.D., Ph.D.	CEO & Director	139.01k	N/A	1951
Mr. Brook G. Riggins C.F.A.	CFO, Secretary & Director	97.35k	15k	1966
Ms. Mary Jo Bagger	Consultant for Clinical Operations	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet medical needs. Its lead product candidate under development is TTI-0102, a prodrug consisting of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. The company is headquartered in Toronto, Canada.

Corporate Governance

Thiogenesis Therapeutics, Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.